Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Summary

This is an expanded access program for eligible participants with a previously treated B-cell cancer who are ineligible for an ongoing pirtobrutinib clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications